SOLUTIONS
Turning bold ideas into real-world solutions
AVITHRAPID | Accelerating Antiviral Innovation
Challenge
Antiviral R&D is hindered by slow development cycles and fragmented coordination between researchers, clinicians, and regulatory bodies—delaying the deployment of effective solutions during outbreaks.
Chelonia’s Role
In AVITHRAPID, a Horizon Europe initiative funded by Swiss Confederation and European Commission with 7.6m Euro, Chelonia leads strategic communication, stakeholder engagement, and ecosystem development to bridge the gap between science and application. Beyond dissemination, Chelonia also drives the exploitation strategy, leveraging its deep knowledge of biotech markets and business models.
Chelonia’s Added Value
By aligning scientific progress with real-world market pathways, Chelonia is preparing AVITHRAPID to evolve from a research project into a sustainable antiviral production platform, positioning it for long-term impact well beyond the project’s duration.
LIGATE | Next-Gen Supercomputing for Drug Discovery
Challenge
Drug discovery demands vast computational resources, especially for molecular docking at scale. Traditional pipelines are often too slow to meet urgent therapeutic needs.
Chelonia’s Role
Within the LIGATE consortium funded by EuroHPC JU with 5.9m Euro, Chelonia contributes to the exploitation and sustainability strategy, ensuring that the project’s innovations in AI-accelerated drug design and HPC are transferred from research environments to commercial and clinical settings.
Chelonia’s Added Value
Chelonia bridged HPC research and pharmaceutical market adoption, translating deep tech outcomes into realistic business and partnership models. Its involvement ensured that LIGATE results were not only scientifically excellent but also positioned for uptake by industry players.
EXSCALATE4COV | Emergency Response through HPC
Challenge
The COVID-19 crisis demanded rapid identification of therapeutic options—a task too time-sensitive for conventional R&D cycles.
Chelonia’s Role
Chelonia, together with a restricted group of research centers and pharma companies, launched the rapid-response consortium funded 2.9m Euro by the EU. Chelonia coordinated communication, stakeholder engagement, and industrial outreach, ensuring real-time visibility and positioning of EXSCALATE4COV as a European reference for rapid-response drug screening.
Chelonia’s Added Value
Thanks to Chelonia’s network and strategic framing, the project gained traction across policymakers, pharma companies, and regulators. Chelonia played a pivotal role in turning a fast-track emergency response into a blueprint for pandemic response. The company also acted as a policy liaison with China government. In 2024 Silvano Coletti, CEO Chelonia, edited and co-authored the Springer book “ExscalateCOV: High-Performance Computing for COVID Drug Discovery” with an introduction of 2013 Nobel Prize Arieh Warshel and conclusions by the EU Deputy Director General Thomas Skordas
AICHEMIST | Explainable AI for Molecules and Next‑Gen Drug Discovery
Challenge
Traditional drug discovery is slow, costly, and often opaque. Predicting the biological, chemical, and toxicological properties of molecules remains a major bottleneck. Standard machine learning models frequently lack interpretability and fail to generalize across novel chemical structures.
Chelonia’s Role
Chelonia is a key partner in AIChemist, a European Marie Skłodowska‑Curie Doctoral Network coordinated by Helmholtz Munich. The project brings together academic excellence and industrial leadership to advance explainable AI for molecular representation and drug discovery. In this initiative, Chelonia supports Helmholtz Munich in the design and execution of scientific communication and dissemination strategies, ensuring broad visibility and long-term impact of the project’s innovations.
Chelonia’s Added Value
Chelonia assembled a cross-disciplinary team and facilitated collaboration with global pharma leaders (Pfizer, Bayer, AstraZeneca, Sanofi, Syngenta), public agencies (European Chemicals Agency, FDA, NIEHS), and top-tier academic institutions. This ecosystem enables the training of molecular-AI specialists and the rapid transfer of interpretable chemical models into industrial and regulatory settings.
AIChemist exemplifies Chelonia’s ability to orchestrate high-impact scientific networks that bridge academia, industry, and public institutions.
OSTROS ENERGIA | A Fast-Track to Green Infrastructure
Challenge
The energy transition needs not only innovation, but execution speed. While hundreds of MW in renewable projects wait in the pipeline, scaling them requires structured capital, trusted governance, and industrial credibility.
Chelonia’s Role
Chelonia co-founded and structured Ostro Energia by assembling a rapid-response investor club, including its own participation, and securing development rights for utility-scale renewable wind projects. Within months, Chelonia negotiated the entry of A2A SpA—one of Italy’s largest multi utilities—which acquired a majority stake to accelerate project deployment.
Chelonia’s Added Value
Acting as both strategic architect and early investor, Chelonia created a high-leverage vehicle able to bridge development vision and industrial execution. By retaining governance during the early phases and mobilizing dozens of millions in growth capital, Chelonia positioned Ostros Energia as a scalable asset for the wind energy market—culminating in its acquisition by A2A SpA and a successful exit.
GENEARROW | Molecular Diagnostics Beyond Earth
Challenge
Space medicine and remote care face a common obstacle: the inability to perform complex molecular diagnostics on-site, due to bulky equipment, skilled labor needs, and lengthy protocols. The challenge intensifies in microgravity environments like the International Space Station (ISS), where standard lab methods are not feasible.
Chelonia’s Role
Through a special purpose vehicle founded in New York, Chelonia engineered and advanced the Gene Arrow platform-a fully automated, pipette-free device for DNA/RNA extraction and analysis based on a NASA-patented microfluidic system. The company secured IP from NASA, coordinated assay development, and led strategic partnerships for dual terrestrial and in-orbit deployment.
Chelonia’s Added Value
Gene Arrow embodies Chelonia’s translational innovation model: transforming high-potential, underutilized space technologies into scalable health tools. Chelonia’s leadership enabled the convergence of molecular medicine, 3D-printed microdevices, and AI-assisted interpretation into a portable diagnostic solution usable by non-specialists. The device was designed to deliver lab-quality results in under 2 hours-from rural clinics to space stations.
Chelonia's horizon scan
Are you a company or research center interested in shaping the future with us? Join our new initiatives and explore potential collaborations. Leave your details and let’s build meaningful synergies together.
